AS a result of the modernization of both society and medical care, life expectancy in developed nations has nearly doubled over the past century, and an 80-year-old person can now anticipate an additional 8 years of life in the United States. 1) Because of longer life spans, the elderly are undoubtedly afflicted with a greater burden of chronic diseases, including cardiovascular disease 2) which is one of the pivotal factors accounting for a large proportion of death and disability in this population. Previous studies [3] [4] [5] have demonstrated that over 30% of patients who died after hospitalization for acute myocardial infarction (AMI) were aged >75 years, and in the United States, an estimated 30% of octogenarians have symptomatic heart disease and an estimated 50% of them will eventually die from it. [6] [7] [8] However, the presence of more comorbid conditions, advanced multivessel disease, and the potential increased need for the management of complications all lessen the enthusiasm for investigating treatment strategies for AMI in this high-risk patient subset. Therefore, this age group has seldom been analyzed separately. [9] [10] [11] Furthermore, there are conflicting data about the long-term efficacy of aggressive treatment and early interventions in the elderly, [12] [13] [14] [15] and it seems that the use of thrombolysis does not improve clinical outcome. 16) Additionally, there are limited reports addressing the efficiency and safety of primary angioplasty for AMI in this high-risk patient population and all of these studies lack control groups. Hence, appropriate treatment for AMI in octogenarian or older patients remains problematic. The purpose of this study was to determine whether primary angioplasty could further improve the short-and long-term clinical outcomes compared with conservative treatment in octogenarian or older patients with AMI.
MATERIALS AND METHODS
Patient population: All consecutive patients 80 years of age or older with AMI admitted to our hospital were not randomized to be registered and constituted the subjects of this study. Group 1 (historical control group) consisted of 111 (8.0%) of 1395 patients who presented with AMI within 48 hours between May 1986 and November 1994 and were admitted to the coronary care unit (CCU). The patients were at least 80 years old and only received conventional treatment without thrombolytic therapy. Between December 1994 and March 2000, emergency Vol 43  No 5 mechanical reperfusion therapy was performed in 688 consecutive patients of any age who presented with AMI within 12 hours (including those with cardiogenic shock within 18 hours) and in this intervention population, 60 (8.7%) patients were 80 years old (group 2). Diagnosis and treatment protocol : The diagnosis of AMI was based on 1) chest pain consistent with ongoing myocardial ischemia lasting for more than 30 minutes with an ST-segment elevation >1 mm in two consecutive inferior, lateral, or precordial leads, 2) typical chest pain lasting for more than 30 minutes with a new onset of complete left bundle branch block; an additional electrocardiographic criterion for both groups was defined as 1 mm ST-segment depression or definite T-wave inversion, or both, and 3) an elevation of creatine kinase (CK) with CK-MB fraction >4% on at least one occasion. There was no restriction based on presentation in cardiogenic shock in group 1 patients.
In the primary angioplasty group, a percutaneous transfemoral approach with an 8 French arterial sheath was used in all patients. Each patient was given a 5000 U bolus of intravenous heparin and 324 mg of chewable aspirin (except those with altered mental status) in the emergency room. After informed consent was obtained, each patient was then transferred immediately to the cardiac catheterization laboratory. Angiography of the presumed non-infarcted vessels was first performed. In order to save time, the same guiding catheter for the presumed infarct-related artery (IRA) was used for both diagnosis and angioplasty. Before angioplasty, the patient received intracoronary heparin (10,000 units), and additional boluses were given as required during the procedure to achieve an activated clotting time of no less than 320 seconds. Before stents were available in our country, primary percutaneous transluminal coronary angioplasty (PTCA) was performed in these patients; however, after stents become available, primary stenting was considered first for these patients and the stent type was selected at the discretion of the operators. Therefore, except for 2 patients who could not receive stent implantation due to heavy calcification and extensive tortuosity of the IRA, a total of 30 stents were implanted in 27 of 60 patients in group 2. Patients were treated with ticlopidine for two weeks if stent implantation was performed. In addition, intravenous heparin was administered after the procedure for 48 hours in patients without intra-aortic balloon pump (IABP) support. For those patients who received IABP support, intravenous heparin infusion was continued until the IABP catheter was removed. The heparin dosage was adjusted to keep the activated partial thromboplastin time at 1.5 to 2 times the control values. Aspirin (324 mg PO once a day) was administered to each patient indefinitely.
In the conservative treatment group, the patients were admitted to CCU and their electrocardiograms were continuously monitored for at least 72 hours. Cardiac catheterization was not performed for these patients. Hemodynamic moni-toring by an arterial line and pulmonary artery balloon catheters was performed in patients with advanced heart failure (Killip 17) score 3 or 4). Because of concern about the risk of intracerebral hemorrhage and fatal or nonfatal disability due to stroke, thrombolytic therapy was not performed in these patients (a universal policy to use no thrombolytic therapy in any octogenarian during this period). However, heparin was routinely administered to each patient in this group for 3-5 days unless there was contraindication. In addition, Aspirin (324 mg PO once a day) was administered to each patient indefinitely.
All other medications, including nitrates, vasopressor agents, digoxin, vasodilator agents, antiarrhythmic drugs, calcium channel blockers, β-blockers, diuretics and angiotensin-converting enzyme inhibitors were used as needed with similar frequency in both groups. Definitions: Cardiogenic shock was defined based on the Killip classification 17) and modified as follows: chest x-ray revealed pulmonary edema with systolic blood pressure (SBP) <90 mm Hg or persistent hypotension with SBP <90 mm Hg and associated low cardiac output with clear lung fields, not related to dysarrhythmia, no response to adequate fluid supply, and the need for vasopressor agent infusion. Cardiogenic shock was further confirmed by the measurement of pulmonary capillary wedge pressure >18 mm Hg and SBP persistent <90 mm Hg by hemodynamic monitoring in the cardiac catheterization laboratory or CCU and associated with signs of tissue hypoperfusion (including altered mental status, decreased urine output, and clammy skin). Procedural success was defined as a reduction to residual stenosis <50% by balloon angioplasty or successful stent implantation at the desired position with a residual stenosis <30% followed by Thrombolysis in Myocardial Infarction (TIMI) 17) grade 3 flow in the IRA. Multivessel disease was defined by a stenosis of >50% in 2 major epicardial coronary arteries. Recurrent ischemia was defined as recurrent chest pain >20 minutes with new ischemic electrocardiographic changes. If these findings were associated with at least a 50% increase in a previous CK-MB trough, reinfarction was diagnosed. Restenosis was defined as 50% stenosis of a previously targeted lesion of the IRA. Cardiac complications included sustained ventricular tachycardia/fibrillation or advanced congestive heart failure (New York Heart Association Functional Class 3 or 4). Non-cardiac complications included acute stroke, respiratory failure requiring mechanical ventilatory support, upper gastrointestinal bleeding requiring blood transfusion, acute renal failure, or sepsis. Data collection: Detailed in-hospital and follow-up data including age, sex, coronary risk factors, Killip score 17) upon presentation, cardiac and non-cardiac complications, comorbid conditions, peak serum CK, CK-MB fractions, and inhospital, 30-day, and long-term adverse events were prospectively collected and entered into a computerized database. Likewise, angiographic results, number of diseased vessels, and angioplasty results were prospectively collected in group 2 patients. Since angiography was not performed in group 1 patients, angiographic variables were not used as indicators for prognosis. Clinical follow-up: All surviving patients in groups 1 and 2 were scheduled to return to follow up in the outpatient clinic every month; therefore, clinical information could be obtained prospectively from each patient. Statistical analysis: Data are expressed as the mean ± SD. Continuous variables were compared using the Student t-test. Categorical variables were compared using the chi-square or Fisher's exact test. The cumulative survival rates were analyzed with actuarial methods, and Kaplan-Meier curves were constructed. All statistical analyses were performed using an SAS system. A P value <0.05 was considered to be statistically significant.
RESULTS
Baseline clinical characteristics: Relevant patient characteristics for both groups are shown in Tables I and II. Group 1 was comprised of 111 patients and group 2 had 60 patients (Table I ). There were no significant differences in the baseline characteristics between the groups. The mean age of the patients in the two groups was similar (83 years). Females accounted for 48.6% and 41.7% of the patients in groups 1 and 2, respectively. The mortality was similar between female and male patients in group 1 (50.9% vs 57.4%, P=0.49) and between female and male patients in group 2 (32.0% vs 28.6%, P=0.78). A high incidence of hypertension (>50%) in these elderly patients was also noted. Furthermore, other comorbidities such as chronic renal insufficiency, diabetes mellitus, chronic obstructive lung disease, and a history of stroke were frequently observed in these patients. There was also no significant difference in terms of cardiac and non-cardiac complications for the same Killip classification between the groups (Table  II) .
Killip classification upon presentation and 24 hours after admission (Table III) :
There were no significant differences in Killip score 1 or 4 upon presentation between the groups. group 2 patients had a significantly higher incidence of Killip score 2 than did group 1 patients upon initial presentation and 24 hours after admission. Conversely, group 1 patients had a significantly higher incidence of Killip score 3 than did group 1 patients upon initial presentation and 24 hours after admission. However, 24 hours after admission, group 1 patients had a higher incidence of progression to higher Killip scores than did group 2 patients. This was especially true for group 1 patients with progression from a Killip score of 1 to 3 and from 3 to 4. Angiographic results in group 2 patients: Balloon angioplasty was performed in 33 (55.0%) patients and stenting was deployed in 27 (45.0%) patients in group 2. The overall procedural success rate was 86.7% (52/60). The procedural success rate was similar between patients receiving stenting or balloon angioplasty [88.9% (24/27) vs. 84.9% (28/33), P=0.72]. Unsuccessful reperfusion included final angiographic results of TIMI grade 2 flow in 4 patients (6.7%) and TIMI grade 1 flow in 4 (6.7%). Three patients died during unsuccessful reperfusion in the first few hours after the procedure. Recurrent ischemia occurred in 2 patients and reinfarction in 2 patients (these patients were treated by balloon angioplasty) in group 2 during hospitalization. Repeated angioplasty (including rescue stenting in 1 patient) was successfully performed in these 4 patients. (Table IV) : The 30-day overall mortality of group 1 patients was significantly higher than that of group 2 patients. The 30-day mortality rate of group 1 patients with Killip scores of 1 and 2 was significantly higher than that of group 2 patients with the same Killip scores. The 30-day mortality rate of group 1 patients with a Killip score of 3 was also significantly higher than that of group 2 patients with the same Killip score. However, the 30-day mortality rates for patients in both groups with a Killip score of 4 were similar. In group 2, the 30-day mortality rate of patients who received At a mean follow-up of 10.9 months (range, 1 to 36 months), the overall mortality of group 1 patients was 47.1% (24/51). Cardiac death occurred in 14 (58.3%) patients, including 9 from congestive heart failure and 5 from sudden death. Non-cardiac death occurred in 10 (41.7%) patients, including 3 patients from cancer, 3 from stroke, and 4 from infection.
Comparison of 30-day mortality rates between groups
At a mean follow-up of 15.1 months (range, 1 to 36 months), the overall mortality of group 2 patients was 28.6% (12/42). Cardiac death occurred in 7 (58.3%) patients (including stenting in 2 patients), including 5 from congestive heart failure, and 2 from sudden death. Non-cardiac death occurred in 5 (41.7%) patients (including stenting in 3 patients), including 2 patients from cancer, 1 from stroke, and 2 from sepsis. Six-month angiographic follow-up was performed in 22 (52.4%) of the remaining 42 patients in group 2 (other patients refused for reasons of being either asymptomatic or too old to undergo cardiac catheterization, or because death had occurred before repeated cardiac catheterization). Ten (45.5%) of the 22 patients had IRA restenosis and the restenosis rate of patients who received balloon angioplasty was higher than that of patients who received stenting, although it did not reach statistical significance (53.8% (7/13) vs 33.3% (3/9), P=0.42). Five (50%) of the 10 patients required mechanical revascularization.
Kaplan-Meier analysis demonstrated that group 2 patients had a significantly higher cumulative survival rate than did group 1 patients (P<0.001) (Figure) . 
DISCUSSION
Effect of advanced age on mortality during AMI: Although patients in their 8th decade constitute a substantial minority of the infarction population 10, 11, 15) (range from 7.6% to 8.1% in previous studies and 8.2% in our study), they represent a high-risk subgroup of patients with AMI 9) and are usually associated with a high in-hospital mortality rate of up to 43%. 10, 15) In the present study, the overall 30-day mortality for the 111 patients treated conservatively was very high (54.1%). Our finding is comparable to those of previous studies 10, 15) and confirms that advanced age with AMI treated conservatively has an unsatisfactory clinical outcome. Impact of primary angioplasty on short-term mortality : The merits of primary angioplasty versus thrombolytic therapy in elderly patients have been debated extensively. 13, 19) Compared with thrombolytic therapy, primary angioplasty in the elderly resulted in a significantly lower incidence of mortality, recurrent ischemic, and reinfarction rates. However, most patients in these two studies 13, 19) Figure. Kaplan-Meier survival curve in group 1 and group 2 patients over 3 years.
were in fact under 80 years of age. Moreover, the potentially higher mortality rate in octogenarians with AMI and the risk of intracerebral hemorrhage and fatal or nonfatal disabling stroke with thrombolytic therapy 20) all lessen the enthusiasm for investigating treatment strategies for AMI in patients who are 80-89 years old. 13, [18] [19] [20] [21] Therefore, there are limited data regarding effective treatment strategies for AMI in this high-risk patient population. [9] [10] [11] 15, 22) To the best of our knowledge, there are only 3 published studies 9, 11, 15) evaluating the efficacy and safety of primary angioplasty for AMI in 80-89 year old patients and addressing the clinical outcome of these patients. In these studies, a high procedural success was achieved (88% to 93%), and the 30-day overall mortality rate varied from 16% to 27.3%. Since these studies lack control groups, the relative merits of primary angioplasty on short-and long-term outcomes may be difficult to assess.
In the present study, we found that patients treated aggressively by primary angioplasty had a significantly lower incidence of in-hospital and 30-day overall mortality than did patients treated conservatively. However, the benefit of primary angioplasty on survival was only observed in those patients without cardiogenic shock (Table IV) . The 30-day mortality rate of patients with cardiogenic shock was extremely high whether the patient was treated with either primary angioplasty or conventional therapy (88.2% vs. 86.1%, P=0.99). Therefore, our data do not support the belief that primary angioplasty offers superior benefits over conventional treatment in octogenarian or older patients with AMI complicated by cardiogenic shock. This is the most important finding which suggests that the value of aggressive intervention with primary angioplasty in these cardiogenic shock patients is questionable, especially in the present era of cost containment and limited medical resources. Impact of primary angioplasty on long-term outcome : The effect of emergency mechanical reperfusion therapy on long-term outcome has been extensively debated. 19, 25) However, the effect of this treatment strategy on long-term outcome in octogenarian or older patients with AMI has rarely been studied. 11) In our study, we found that patients treated by primary angioplasty had a significantly higher cumulative survival rate than did patients treated conservatively at 3-year followup (Figure) . The positive impact of primary angioplasty on long-term outcome for octogenarian or older patients was also observed in a previous study.
11) Therefore, the short-term beneficial effect of primary angioplasty may be extended to the long-term outcome in octogenarian or older patients with AMI but without the complications of cardiogenic shock.
Sex distribution, incidence of cardiogenic shock, and impact of primary angioplasty on Killip score: Several distinctive clinical features were observed in this study. First, we found that females constituted nearly half of the infarction population, which is consistent with the results of previous investigations. 10, 11, 22) Furthermore, our results indicate that female patients do not have worse clinical outcomes than male patients. Second, the incidence of cardiogenic shock in a previous study (26.2%) 10) and in ours (22.2% upon initial presentation) exceeded those of other previous studies (7.2% to 10.0%), 23, 24) and this contributes to higher in-hospital and 30-day mortalities in patients treated conservatively in previous studies and ours. Third, 35 of 111 (31.5%) patients in group 1 had chest pain >24 hours upon initial presentation. Furthermore, patients treated conservatively had a significantly higher incidence of progression to higher Killip scores than did patients treated by primary angioplasty (Table II) . This could explain why group 1 patients had a significantly higher incidence of Killip score 3 and a significantly lower incidence of Killip score 2 than group 2 patients. Moreover, this implies that early and aggressive management in octogenarian or older patients without cardiogenic shock may rescue and preserve a greater amount of viable myocardium.
Our study has 3 limitations. First, since these 2 groups were non-contemporaneous, direct comparisons are limited, for it has been shown that both medical and invasive therapy have improved over time. Nevertheless, the subjects were enrolled in a chronologically consecutive manner, which would eliminate the potential for physician bias in the selection of treatment strategy. Second, platelet glycoprotein IIb/IIIa receptor blockades, which have been shown to improve clinical outcomes in primary PTCA, 25) were not used in this study because these agents were not available in our country during the study period. Whether adjunctive therapy with platelet glycoprotein IIb/IIIa blockade could improve the clinical outcome of octogenarian or older patients with AMI remains to be determined. Third, this study does nothing to resolve the issue of how angioplasty would compare with thrombolysis in advanced age.
In conclusion, our study indicates that primary angioplasty is feasible and effective, and can improve both 30-day and long-term survival compared to that with conservative treatment in octogenarian or older patients with AMI but without cardiogenic shock.
